Dingdang Health, a Chinese online pharmacy business that raised $220 million in funding earlier this month, has filed for a Hong Kong IPO.
Insilico Medicine, which leverages artificial intelligence (AI) technology to speed up the drug development process, has closed a $255 million Series C funding round led by Warburg Pincus.
PE-backed Abbisko Therapeutics, which focuses on the discovery and development of innovative and differentiated small molecule oncology therapies, has filed for a Hong Kong IPO.
Mandala Capital is helping Indian food and pharma testing laboratory EFRAC distinguish itself against a field of ragtag competitors. Personnel, networks, and technology are the critical inputs
Australian investors see hope in ENA Respiratory, a nasal spray specialist aiming to complement global COVID-19 vaccine programs with an immune system-boosting product
Nuevocor, a preclinical biotech company specializing in gene therapy for heart disease, has closed an oversubscribed Series A round with $24 million in commitments.
Nutshell Therapeutics, a Chinese drug developer, has raised a $20 million Series A round led by Matrix Partners China.
Chinese healthcare big data company LinkDoc Technology, which counts New Enterprise Associates (NEA), China Broadband Capital, and Temasek Holdings among its investors, has filed for an IPO in the US.
Yonghe Medical Group, a Chinese hair healthcare specialist best known for hair transplants, is targeting a Hong Kong IPO. Its largest external shareholder is CPE, formerly CITIC Private Equity.
ENA Respiratory, an Australian biotech company developing a nasal spray for the prevention of COVID-19, has raised A$32 million ($25 million) with support from local venture capital investor Brandon Capital.
Chinese B2B pharmaceutical trading platform Yaoshibang has raised $270 million from Guangdong Pearl River Investment, Baidu, Sunshine Insurance, Green Pine Capital Partners, Guangzhou government-backed S Fund, and an undisclosed sovereign wealth fund.
Tata Group’s digital unit has continued its investment spree, dipping into India’s healthcare and fitness spaces with the acquisition of telemedicine platform 1mg Technologies and a $75 million commitment to CureFit.
QitanTech, a gene sequencing start-up also known as Qitan Technology, has raised a RMB400 million ($63 million) Series B round led by Hillhouse Capital and a VC arm of CDH Investments.
TPG Capital has led a $220 million round for Chinese online pharmacy services provider Dingdang Health.
SimCere Diagnostics, the diagnostics arm of Hong Kong-listed SimCere Pharmaceutical Group, has raised RMB600 million ($94 million) in Series B funding led by CITIC Securities and CITIC Medical & Health Fund.
Orchid Asia has achieved a first close of $1.1 billion on its eighth fund, five months after launching the vehicle with a full target of $1.6 billion.
Australian middle-market private equity firm CPE has agreed to sell cord blood banking business Cell Care to Generate Life Sciences, a US-based provider of cellular services for fertility and therapeutic purposes.
Chinese technology and healthcare investor Oceanpine Capital has closed its Hardcore Technology Investment Fund on RMB2 billion ($312 million). LPs include government guidance funds and fund-of-funds in Suzhou, where the new vehicle is based.
Stemirna Therapeutics, which claims to be the first biotech company to bring an mRNA therapeutics and nanomedicine platform to China, has raised $200 million in funding.
China-focused venture capital fund-of-funds Unicorn Capital Partners has closed its latest vehicle at the hard cap of $450 million. The process took six months and the fund was oversubscribed
Heritas Capital, a Singapore-based private equity firm sponsored by industrial conglomerate IMC Group, has reached a first close of $60 million on a pan-Asia impact investment fund.
L Catterton has led a $40 million Series B round for Singapore’s Zenyum, a company that makes 3D-printed dental products.
With big pharma scaling back early-stage discovery, CBC Group is keen to incubate biotech start-ups developing drugs from scratch. NiKang Therapeutics is the first to secure wider investor attention
Shanghai-based Yingke Private Equity has raised RMB10 billion ($1.57 billion) for its latest renminbi-denominated fund as well as an undisclosed sum for a third US dollar vehicle.